Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

NCT06948786 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Grade 1 Follicular Lymphoma
Grade 2 Follicular Lymphoma
Grade 3a Follicular Lymphoma
Recurrent Follicular Lymphoma
Refractory Follicular Lymphoma

Interventions

DRUG: Pirtobrutinib
BIOLOGICAL: Mosunetuzumab
PROCEDURE: Biospecimen Collection
PROCEDURE: Biopsy Procedure
PROCEDURE: Computed Tomography
PROCEDURE: Positron Emission Tomography
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
OTHER: Questionnaire Administration

Sponsor

University of Washington

Collaborators

[object Object]